Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.28)
# 350
Out of 5,179 analysts
233
Total ratings
47.18%
Success rate
17.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $150 → $136 | $75.82 | +79.37% | 15 | Mar 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $182.69 | +23.71% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $66.13 | +39.12% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $13.34 | +4.95% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $128.32 | +36.38% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $33.67 | +137.60% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $62.50 | +13.60% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $16.15 | -25.70% | 3 | Dec 8, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $6.37 | +198.27% | 5 | Nov 12, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $64.62 | +22.25% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $12.85 | +117.90% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $14.97 | -86.64% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $4.31 | +201.62% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.41 | +649.48% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $19.38 | +183.80% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $20.75 | +15.66% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $60.09 | +41.45% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $28.70 | -5.92% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.72 | +840.86% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $3.05 | +31.15% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.37 | +191.97% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $4.96 | +182.26% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.70 | +35.14% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.74 | +9.49% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.22 | +719.67% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $41.53 | -47.03% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $8.37 | +1,674.19% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.68 | +8,684.77% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.96 | +51.52% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $10.01 | +6,373.53% | 6 | May 8, 2020 |
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Overweight
Price Target: $150 → $136
Current: $75.82
Upside: +79.37%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $182.69
Upside: +23.71%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $66.13
Upside: +39.12%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $13.34
Upside: +4.95%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $128.32
Upside: +36.38%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $33.67
Upside: +137.60%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $62.50
Upside: +13.60%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $16.15
Upside: -25.70%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $6.37
Upside: +198.27%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $64.62
Upside: +22.25%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $12.85
Upside: +117.90%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $14.97
Upside: -86.64%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $4.31
Upside: +201.62%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.41
Upside: +649.48%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $19.38
Upside: +183.80%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $20.75
Upside: +15.66%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $60.09
Upside: +41.45%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $28.70
Upside: -5.92%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $3.72
Upside: +840.86%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $3.05
Upside: +31.15%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.37
Upside: +191.97%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $4.96
Upside: +182.26%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.70
Upside: +35.14%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.74
Upside: +9.49%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.22
Upside: +719.67%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $41.53
Upside: -47.03%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $8.37
Upside: +1,674.19%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.68
Upside: +8,684.77%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.96
Upside: +51.52%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $10.01
Upside: +6,373.53%